| Texto completo | |
| Autor(es): |
Campello, R. S.
[1]
;
Alves-Wagner, A. B.
[1]
;
Lucas, T. F.
[2]
;
Mori, R. C.
[1]
;
Furuya, D. T.
[1]
;
Porto, C. S.
[2]
;
Machado, U. F.
[1]
Número total de Autores: 7
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508900 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Pharmacol, Escola Paulista Med, Sect Expt Endocrinol, Sao Paulo - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | CURRENT TOPICS IN MEDICINAL CHEMISTRY; v. 12, n. 19, p. 2059-2069, OCT 2012. |
| Citações Web of Science: | 12 |
| Resumo | |
Type 2 diabetes mellitus is characterized by disruption in glycemic homeostasis, involving impaired insulin-induced glucose disposal. For that, reduced glucose transporter GLUT4, encoded by Slc2a4 gene, plays a fundamental role. Conversely, increase in Slc2a4/GLUT4 expression improves glycemic homeostasis. Recent studies have proposed that estradiol is able to modulate Slc2a4 expression, according to distinct effects upon estrogen receptors ESR1/ESR2. We hypothesize that ESR1-agonist effect could stimulate Slc2a4 expression; thus, increasing cellular glucose disposal, which could be beneficial to glycemic control. Differentiated 3T3-L1 adipocytes were treated (24 hours) with selective ESR1-agonist PPT 1,3,5-tris(4-hydroxyphenyl)-4- propyl-1H-pyrazole, selective ESR1-antagonist MPP 1,3-Bis(4-hydroxyphenyl)-4- methyl-5-{[}4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride, and selective ESR2 agonist DPN 2,3-bis(4-Hydroxyphenyl)-propionitrile, with/without 17 beta-estradiol (E2). We analyzed Slc2a4 mRNA (real time PCR) and GLUT4 protein (Western blotting) expression, transcriptional activity of the Slc2a4 repressor Nuclear Factor-kappa B (NF-kappa B) (electrophoretic mobility shift assay), and cellular glucose disposal (2-deoxi-D-{[}H-3]glucose uptake, 2-DG). ESR1-agonist PPT enhanced Slc2a4/GLUT4 expression (similar to 30%) in the absence or presence of 0.1 and 10 nmol/L E2, and decreased the NF-kappa B binding activity (similar to 50%). Conversely, ESR1-antagonist MPP, together with E2, decreased Slc2a4/GLUT4 expression (20-40%) and increased NF-kappa B binding activity (similar to 30%). Furthermore, treatment with ESR2-agonist DPN decreased Slc2a4/GLUT4 expression (20-50%). 2-DG uptake was modulated in parallel to that observed in GLUT4 protein. The present results reveal that ESR1 activity enhances, whereas ESR2 activity represses, Slc2a4/GLUT4 expression. These effects are partially mediated by NF-kappa B, and allow parallel changes in adipocyte glucose disposal. Furthermore, the data provide evidences that ESR1-agonist PPT, as a Slc2a4/GLUT4 enhancer, can be a promising coadjuvant d(r)ug for diabetes mellitus therapy. (AU) | |
| Processo FAPESP: | 09/02217-1 - Regulação da expressão do gene do GLUT4 pelo estrógeno: Papel dos receptores ER alfa e ER beta. |
| Beneficiário: | Raquel Saldanha Campello |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 07/50554-1 - Transportadores de glicose e diabetes mellitus: contribuicao ao conhecimento da regulacao da glicemia e do desenvolvimento de complicacoes. |
| Beneficiário: | Ubiratan Fabres Machado |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |